After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate ...

Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the lack of a medication ...

ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new ...

AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the ...

Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already ...

In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

With China's growing dominance in the biopharma sector as a hotspot for drug asse | A group of over 20 global pharma leaders ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin ...